-IANS Finance Minister Pranab Mukherjee Friday announced a hike of over 21 per cent in the budget allocation for providing free and compulsory education to children below 14 years. "I proposed an increase in allocation by 21.7 per cent for RTE ( Right to Education) -Sarva Shiksha Abhiyan to Rs.25,555 crore," Mukherjee said in parliament. The Sarva Shiksha Abhiyan is implemented in partnership with state governments and covers nearly 192 million children across...
More »SEARCH RESULT
A life saver-Shamnad Basheer
Compulsory licence can go a long way to ensure access to cheaper drugs In a momentous development, the Indian patent office issued the ever-compulsory licence in a highly contentious pharmaceutical patent case. The decision is a thumping victory for several patients and health activists who have been fighting what can only be labelled as highly inequitable pricing strategies by multinational drug firms for the past several decades. In August 2011, Natco, an...
More »A historic move to make drugs affordable-G Ananthakrishnan
India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...
More »Bayer is set to challenge ruling
-AFP Bayer AG said, on Tuesday, it was mulling ways to challenge a ground-breaking Indian ruling allowing a local firm to produce a vastly cheaper copy of a cancer drug made by the German pharmaceutical giant. The ruling on Monday by India's Controller-General of Patents marked the first time a so-called ‘compulsory licence' for production of a patented drug has been granted in India, known as a global generics drug powerhouse. Evaluating options “We...
More »Road to cheaper drugs by Rupali Mukherjee
The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases. More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...
More »